{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T08:19:20Z","timestamp":1791533960105,"version":"4.3.4"},"reference-count":23,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Urologic Oncology: Seminars and Original Investigations"],"published-print":{"date-parts":[[2025,9]]},"DOI":"10.1016\/j.urolonc.2025.04.010","type":"journal-article","created":{"date-parts":[[2025,5,23]],"date-time":"2025-05-23T07:19:41Z","timestamp":1747984781000},"page":"521.e19-521.e27","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["Prognostic significance of pathologic response to neoadjuvant chemotherapy in muscle-invasive urothelial carcinoma of the bladder with histologic subtype"],"prefix":"10.1016","volume":"43","author":[{"given":"Seth L.","family":"Teplitsky","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Will","family":"Cranford","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joon Kyung","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Spencer","family":"Bell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sydney","family":"Strup","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Derek","family":"Allison","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amanda","family":"Buchanan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zin","family":"Myint","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen E.","family":"Strup","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frances","family":"Martin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akshay","family":"Sood","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashish M.","family":"Kamat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher J.","family":"McLouth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8098-901X","authenticated-orcid":false,"given":"Patrick J.","family":"Hensley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"9","key":"10.1016\/j.urolonc.2025.04.010_bib0001","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1056\/NEJMoa022148","article-title":"Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer","volume":"349","author":"Grossman","year":"2003","journal-title":"N Engl J Med"},{"issue":"16","key":"10.1016\/j.urolonc.2025.04.010_bib0002","doi-asserted-by":"crossref","first-page":"2171","DOI":"10.1200\/JCO.2010.32.3139","article-title":"International phase III trial assessing neoadjuvant cisplatin, methotrexate, and vinblastine chemotherapy for muscle-invasive bladder cancer: long-term results of the BA06 30894 trial","volume":"29","year":"2011","journal-title":"J Clin Oncol"},{"issue":"5","key":"10.1016\/j.urolonc.2025.04.010_bib0003","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1016\/j.eururo.2022.07.002","article-title":"The 2022 World Health Organization classification of tumors of the urinary system and male genital organs-Part B: prostate and urinary tract tumors","volume":"82","author":"Netto","year":"2022","journal-title":"Eur Urol"},{"issue":"2","key":"10.1016\/j.urolonc.2025.04.010_bib0004","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1097\/JU.0000000000003778","article-title":"Long-term oncological outcomes in patients diagnosed with nonmetastatic plasmacytoid variant of bladder Cancer: a 20-year University of Texas MD Anderson Cancer Center experience","volume":"211","author":"Sood","year":"2024","journal-title":"J Urol"},{"issue":"6","key":"10.1016\/j.urolonc.2025.04.010_bib0005","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1097\/JU.0000000000001305","article-title":"A systematic review and meta-analysis of variant histology in urothelial carcinoma of the bladder treated with radical cystectomy","volume":"204","author":"Mori","year":"2020","journal-title":"J Urol"},{"issue":"4","key":"10.1016\/j.urolonc.2025.04.010_bib0006","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1016\/j.euf.2019.09.003","article-title":"What is the significance of variant histology in urothelial carcinoma?","volume":"6","author":"Lobo","year":"2020","journal-title":"Eur Urol Focus"},{"issue":"1","key":"10.1016\/j.urolonc.2025.04.010_bib0007","doi-asserted-by":"crossref","first-page":"e53","DOI":"10.1016\/j.clgc.2023.07.005","article-title":"Neoadjuvant chemotherapy prior to radical cystectomy for muscle-invasive bladder cancer with variant histology: a systematic review and meta-analysis of survival outcomes and pathological features","volume":"22","author":"Kim","year":"2024","journal-title":"Clin Genitourin Cancer"},{"issue":"1","key":"10.1016\/j.urolonc.2025.04.010_bib0008","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1097\/JU.0000000000001325","article-title":"Pathological and survival outcomes associated with variant histology bladder cancers managed by cystectomy with or without Neoadjuvant chemotherapy","volume":"205","author":"Hajiran","year":"2021","journal-title":"J Urol"},{"issue":"2","key":"10.1016\/j.urolonc.2025.04.010_bib0009","doi-asserted-by":"crossref","first-page":"133","DOI":"10.3233\/BLC-240008","article-title":"Neoadjuvant Cisplatin, Gemcitabine, and Docetaxel in Sarcomatoid bladder cancer: clinical activity and whole transcriptome analysis","volume":"10","author":"Johnson Iii","year":"2024","journal-title":"Bladder Cancer"},{"issue":"2","key":"10.1016\/j.urolonc.2025.04.010_bib0010","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1016\/j.euf.2024.05.015","article-title":"What about variant histologies in bladder cancer?","volume":"10","author":"Day","year":"2024","journal-title":"Eur Urol Focus"},{"issue":"5","key":"10.1016\/j.urolonc.2025.04.010_bib0011","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1097\/MOU.0000000000001022","article-title":"The past, present, and future of pT0 in bladder cancer clinical trials","volume":"32","author":"Schober","year":"2022","journal-title":"Curr Opin Urol"},{"issue":"5","key":"10.1016\/j.urolonc.2025.04.010_bib0012","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1016\/j.eururo.2017.05.016","article-title":"Oncologic outcomes for patients with residual cancer at cystectomy following neoadjuvant chemotherapy: a pathologic stage-matched analysis","volume":"72","author":"Bhindi","year":"2017","journal-title":"Eur Urol"},{"issue":"1","key":"10.1016\/j.urolonc.2025.04.010_bib0013","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1097\/JU.0000000000003981","article-title":"Treatment of non-metastatic muscle-invasive bladder cancer: AUA\/ASCO\/SUO GUIDELINE (2017; Amended 2020, 2024)","volume":"212","author":"Holzbeierlein","year":"2024","journal-title":"J Urol"},{"issue":"4","key":"10.1016\/j.urolonc.2025.04.010_bib0014","doi-asserted-by":"crossref","first-page":"216","DOI":"10.6004\/jnccn.2024.0024","article-title":"Bladder cancer, version 3.2024","volume":"22","author":"Flaig","year":"2024","journal-title":"J Natl Compr Canc Netw"},{"issue":"1","key":"10.1016\/j.urolonc.2025.04.010_bib0015","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.eururo.2023.08.016","article-title":"European Association of Urology Guidelines on muscle-invasive and metastatic bladder cancer: summary of the 2023 Guidelines","volume":"85","author":"Alfred Witjes","year":"2024","journal-title":"Eur Urol"},{"issue":"1","key":"10.1016\/j.urolonc.2025.04.010_bib0016","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.juro.2013.07.061","article-title":"Refining patient selection for neoadjuvant chemotherapy before radical cystectomy","volume":"191","author":"Culp","year":"2014","journal-title":"J Urol"},{"issue":"5","key":"10.1016\/j.urolonc.2025.04.010_bib0017","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1097\/JU.0000000000001943","article-title":"Progression of disease after Bacillus Calmette-Gu\u00e9rin therapy: refining patient selection for neoadjuvant chemotherapy before radical cystectomy","volume":"206","author":"Hensley","year":"2021","journal-title":"J Urol"},{"issue":"4","key":"10.1016\/j.urolonc.2025.04.010_bib0018","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1097\/JU.0000000000001855","article-title":"Pathological downstaging and survival outcomes associated with Neoadjuvant chemotherapy for variant histology muscle invasive bladder cancer","volume":"206","author":"Chakiryan","year":"2021","journal-title":"J Urol"},{"issue":"18","key":"10.1016\/j.urolonc.2025.04.010_bib0019","doi-asserted-by":"crossref","first-page":"3155","DOI":"10.1002\/cncr.32169","article-title":"Tumor downstaging as an intermediate endpoint to assess the activity of neoadjuvant systemic therapy in patients with muscle-invasive bladder cancer","volume":"125","author":"Martini","year":"2019","journal-title":"Cancer"},{"issue":"35","key":"10.1016\/j.urolonc.2025.04.010_bib0020","doi-asserted-by":"crossref","first-page":"5437","DOI":"10.1200\/JCO.23.00307","article-title":"Definitions, end points, and clinical trial designs for Bladder Cancer: recommendations from the Society for Immunotherapy of Cancer and the International Bladder Cancer Group","volume":"41","author":"Kamat","year":"2023","journal-title":"J Clin Oncol"},{"issue":"4","key":"10.1016\/j.urolonc.2025.04.010_bib0021","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1111\/bju.16333","article-title":"Trimodal therapy effect on survival in urothelial vs non-urothelial bladder cancer","volume":"134","author":"de Angelis","year":"2024","journal-title":"BJU Int"},{"issue":"8","key":"10.1016\/j.urolonc.2025.04.010_bib0022","doi-asserted-by":"crossref","first-page":"1650","DOI":"10.1016\/j.urolonc.2012.04.009","article-title":"Variant (divergent) histologic differentiation in urothelial carcinoma is under-recognized in community practice: impact of mandatory central pathology review at a large referral hospital","volume":"31","author":"Shah","year":"2013","journal-title":"Urol Oncol"},{"key":"10.1016\/j.urolonc.2025.04.010_bib0023","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/j.urology.2016.01.048","article-title":"Change in management based on pathologic second opinion among bladder cancer patients presenting to a comprehensive cancer center: implications for clinical practice","volume":"93","author":"Luchey","year":"2016","journal-title":"Urology"}],"container-title":["Urologic Oncology: Seminars and Original Investigations"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1078143925001693?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1078143925001693?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,8,11]],"date-time":"2025-08-11T11:36:20Z","timestamp":1754912180000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1078143925001693"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9]]},"references-count":23,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2025,9]]}},"alternative-id":["S1078143925001693"],"URL":"https:\/\/doi.org\/10.1016\/j.urolonc.2025.04.010","relation":{},"ISSN":["1078-1439"],"issn-type":[{"value":"1078-1439","type":"print"}],"subject":[],"published":{"date-parts":[[2025,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Prognostic significance of pathologic response to neoadjuvant chemotherapy in muscle-invasive urothelial carcinoma of the bladder with histologic subtype","name":"articletitle","label":"Article Title"},{"value":"Urologic Oncology: Seminars and Original Investigations","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.urolonc.2025.04.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}